With ~100M cash at start of FY, and revolving credit facilities approved until 2018, if they get anywhere near guidance then you wouldn't think so in the short term.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress